SG&A at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s SG&A?
- The Oncology Institute, Inc. (TOI) reported SG&A of $28.21M in Q1 2026.
- How has The Oncology Institute, Inc.'s SG&A changed year-over-year?
- The Oncology Institute, Inc.'s SG&A increased by 11.2% year-over-year, from $25.38M to $28.21M.
- What is the long-term trend for The Oncology Institute, Inc.'s SG&A?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s SG&A has grown at a 6.1% compound annual growth rate (CAGR), from $83.37M to $105.57M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.